Medisun Precision Medicine Ltd. is a biotechnology company, which focuses on developing novel neurological therapies to be directly delivered into specific regions of the brain. It portfolio includes ACX-31 program to deliver two chemotherapy drugs, temozolomide in combination with BCNU, locally to brain tumor sites. The company was founded on August 29, 2012 and is headquartered in Majuro, Marshall Islands.
Company profile
Ticker
MPME
Exchange
CEO
Sophia Yaqi Sun
Employees
Location
Fiscal year end
Industry (SIC)
Former names
Accurexa Inc., Cyto Wave Technologies Inc.
SEC CIK
Corporate docs
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
10 Sep 20
10-Q
2017 Q2
Quarterly report
16 Aug 17
8-K
Amendments to Articles of Incorporation or Bylaws
16 Aug 17
NT 10-Q
Notice of late quarterly filing
15 Aug 17
8-K
Entry into a Material Definitive Agreement
11 Aug 17
DEF 14C
Information statement
28 Jul 17
8-K
Entry into a Material Definitive Agreement
25 Jul 17
PRE 14C
Preliminary information
18 Jul 17
8-K
Entry into a Material Definitive Agreement
10 Jul 17
8-K
Amendments to Articles of Incorporation or Bylaws
3 Jul 17
Latest ownership filings
SC 13G/A
Beneficial ownership report (amended)
4 Jan 18
SC 13D
Medisun Precision Medicine Ltd.
20 Jul 17
4
Change in insider ownership
12 Jun 17
SC 13D/A
Accurexa Inc.
12 Jun 17
3
Initial statement of insider ownership
30 May 17
SC 13D
Accurexa Inc.
26 May 17
3
LISHA HUANG
25 May 17
3
YAQI SUN
25 May 17
3
STEFAN MOLL
6 Apr 17
3
BRYAN LEE
25 Jan 17
Institutional ownership, Q3 2019
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|